{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:33:39Z","timestamp":1788791619201,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key R&D Program of China","award":["2017YFC0907100"],"award-info":[{"award-number":["2017YFC0907100"]}]},{"name":"Guiding Project on Medicine & Health in Xiamen, China","award":["3502Z20209048"],"award-info":[{"award-number":["3502Z20209048"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2023,1,31]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Risk of non-obese or lean non-alcoholic fatty liver disease (NAFLD) for cancer in patients with type 2 diabetes mellitus (T2DM) is less known. We aimed to evaluate independent associations of NAFLD, especially non-obese or lean NAFLD, and body mass index (BMI) on risks of cancer in patients with T2DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>Cross-sectional analyses of baseline information on a cohort of 233\u2009patients with T2DM were conducted in Xiamen, China. NAFLD was identified by hepatic ultrasonography diagnosis of hepatic steatosis without excessive alcohol consumption, viral or autoimmune liver disease. Fibrosis-4 (FIB-4) score was calculated to quantify severity of hepatic fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All types of cancers were diagnosed on 19 (8.2%) patients. Prevalence of cancer was significantly higher in those with NAFLD than those without (15.5% vs 4.0%, p=0.002), but were not significantly different among BMI categories (6.8%, 13.7% and 6.5% for those with underweight or normal weight (n=74), overweight (n=51) and obesity (n=108), respectively, p=0.258). With adjustment for potential confounding factors in the multivariable logistic regression models, NAFLD was significantly associated with increased risk of cancer with the adjusted OR (95%\u2009CI) of 5.969 (1.349 to 26.413, p=0.019). Stratified analyses across BMI categories found similar association of NAFLD with risk of cancer for those non-obese or lean (the adjusted OR (95%\u2009CI) 17.446 (1.690 to 180.095, p=0.016)) but not for those with either overweight (OR (95%\u2009CI) 11.642 (0.832 to 162.963, p=0.068) or obesity (OR (95%\u2009CI) 0.917 (0.170 to 4.954, p=0.920). FIB-4 score was not significantly associated with risk of cancer for all subjects or stratified across BMI categories. BMI was not significantly associated with risk of cancer for all patients or stratified by NAFLD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NAFLD, even non-obese or lean NAFLD, was independently associated with increased risk of cancer in patients with T2DM. Screening and management of NAFLD, especially for those with underweight or normal weight, should be strengthened from the perspective of improving prevention and management of cancer in patients with T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2022-003066","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T11:10:11Z","timestamp":1676459411000},"page":"e003066","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus"],"prefix":"10.1136","volume":"11","author":[{"given":"Ning","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Fudan University Xiamen Branch, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Fudan University Xiamen Branch, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Fudan University Xiamen Branch, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Fudan University Xiamen Branch, Xiamen, Fujian, China"},{"name":"Department of Endocrinology, Fudan University Shanghai, Yangpu, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-9780","authenticated-orcid":false,"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[{"name":"Epidemiology Research Unit, Translational Medicine Research Center, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"2025073112224266000_11.1.e003066.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"2025073112224266000_11.1.e003066.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"2025073112224266000_11.1.e003066.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10029"},{"key":"2025073112224266000_11.1.e003066.4","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"2025073112224266000_11.1.e003066.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0204"},{"key":"2025073112224266000_11.1.e003066.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73668-y"},{"key":"2025073112224266000_11.1.e003066.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60886-2"},{"key":"2025073112224266000_11.1.e003066.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2013.05.006"},{"key":"2025073112224266000_11.1.e003066.9","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.3390\/cancers13225735","article-title":"Diabetes and cancer: risk, challenges, management and outcomes","volume":"13","author":"Shahid","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025073112224266000_11.1.e003066.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011775"},{"key":"2025073112224266000_11.1.e003066.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3093"},{"key":"2025073112224266000_11.1.e003066.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6"},{"key":"2025073112224266000_11.1.e003066.13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073112224266000_11.1.e003066.14","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes","volume":"72","author":"Natarajan","year":"2020","journal-title":"Hepatology"},{"key":"2025073112224266000_11.1.e003066.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.010"},{"key":"2025073112224266000_11.1.e003066.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225844","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: from epidemiology to diagnostic approach","volume":"13","author":"Grgurevic","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025073112224266000_11.1.e003066.17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050717","article-title":"Non-alcoholic fatty liver disease and extra-hepatic cancers","volume":"17","author":"Sanna","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025073112224266000_11.1.e003066.18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jceh.2020.04.018","article-title":"The association between nonalcoholic fatty liver disease and risk of cardiovascular disease, stroke, and extrahepatic cancers","volume":"11","author":"Veracruz","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"2025073112224266000_11.1.e003066.19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4326"},{"key":"2025073112224266000_11.1.e003066.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"2025073112224266000_11.1.e003066.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60318-4"},{"key":"2025073112224266000_11.1.e003066.22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073112224266000_11.1.e003066.23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30908"},{"key":"2025073112224266000_11.1.e003066.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S002"},{"key":"2025073112224266000_11.1.e003066.25","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.APPGL"},{"key":"2025073112224266000_11.1.e003066.26","first-page":"163","article-title":"Chinese liver disease association: guidelines for management of nonalcoholic fatty liver disease. an updated and revised edition","volume":"18","author":"Jian-gao","year":"2010","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"2025073112224266000_11.1.e003066.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"2025073112224266000_11.1.e003066.28","unstructured":"WHO\/IASO\/IOTF . The asia-pacific perspective: redefining obesity and its treatment. Melbourne Health Communications Australia; 2000."},{"key":"2025073112224266000_11.1.e003066.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"2025073112224266000_11.1.e003066.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"2025073112224266000_11.1.e003066.31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cld.1006","article-title":"Molecular mechanisms linking nonalcoholic steatohepatitis to cancer","volume":"17","author":"Wegermann","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2025073112224266000_11.1.e003066.32","doi-asserted-by":"crossref","unstructured":"Mantovani A , Petracca G , Beatrice G , et al . Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2021:gutjnl-2021-324191. doi:10.1136\/gutjnl-2021-324191","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"2025073112224266000_11.1.e003066.33","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/jgh.15353","article-title":"A review of non-alcoholic fatty liver disease in non-obese and lean individuals","volume":"36","author":"Ahadi","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2025073112224266000_11.1.e003066.34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.clnu.2018.08.008","article-title":"Lean non-alcoholic fatty liver disease","volume":"38","author":"Wang","year":"2019","journal-title":"Clin Nutr"},{"key":"2025073112224266000_11.1.e003066.35","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13543"},{"key":"2025073112224266000_11.1.e003066.36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/EJE-19-0143","article-title":"Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study","volume":"181","author":"Sinn","year":"2019","journal-title":"Eur J Endocrinol"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2022-003066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:22:50Z","timestamp":1753989770000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2022-003066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,15]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjdrc-2022-003066"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2022-003066","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}